Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank-check company targeting the domestic pharmaceutical and drug manufacturing sector. The company filed an amended S-1/A registration statement with the SEC on January 6, 2025, as it worked toward completing its initial public offering, placing its expected IPO year in 2025. The SPAC's name and stated focus reflect a broader industry interest in reshoring U.S. pharmaceutical production and supply chain resilience. The S-1/A amendment is a standard step in the SPAC IPO process, allowing sponsors to update disclosures and offering terms prior to pricing. Visit SpacDesk and sign up for full data, filing history, and real-time deal tracking on DMAAR and hundreds of other SPACs.